Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial Hypertension
Tóm tắt
Hospitalization is an important clinical factor associated with survival and rehospitalization in patients with pulmonary arterial hypertension (PAH). Thus, this study examined treatment patterns before and after hospitalization in the US-specific population. Adult PAH patients in the United States were identified using the Optum® Clinformatics® database from January 1, 2014, to June 30, 2019, and were required to have continuous health plan enrollment for at least 6 months prior to the first (index) hospitalization through at least 90 days post-discharge. Baseline patient characteristics were evaluated from 6 months prior to through the index hospitalization. PAH treatment patterns were examined from 30 days pre-index admission (pre-hospitalization) and 90 days post-index hospital discharge (post-hospitalization), and stratified by therapy type: monotherapy, double- or triple-combination therapy, or no PAH therapy. A total of 3116 hospitalized patients with PAH met selection criteria. The mean age and Charlson comorbidity index score were 68.1 years and 5.1, respectively. In the pre- and post-hospitalization periods (all-cause), respectively, patients prescribed monotherapy were most common (from 64.8% pre- to 51.9% post-hospitalization), followed by patients with no evidence of PAH therapy (from 14.6 to 28.5%). Among PAH-related hospitalizations, patients with monotherapy were also most common (from 60.8% pre- to 49.1% post-hospitalization), followed by patients with no evidence of PAH therapy (from 10.0 to 22.8%). The majority of patients with all-cause hospitalizations (72.8%) had no therapy modification; 20.0% de-escalated therapy (including 15.0% from monotherapy to no therapy) and 6.1% escalated therapy (including 2.2% from no therapy to monotherapy and 3.2% from monotherapy to double or triple therapy). Inpatient admissions did not appear to drive changes in PAH therapy management, as monotherapy predominated, and most patients had no therapy modification within 90 days of a hospitalization. These results warrant future research to understand the reasons behind the limited treatment intensification observed and the impact of post-hospitalization optimization on clinical and economic outcomes.
Tài liệu tham khảo
Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37(1):67–119. https://doi.org/10.1093/eurheartj/ehv317.
National Organization for Rare Disorders. Pulmonary arterial hypertension. https://rarediseases.org/rare-diseases/pulmonary-arterial-hypertension/#:~:text=New%20cases%20are%20estimated%20to,frequency%20of%20patients%20with%20PAH. Accessed 2 Feb 2021.
Farber HW, Miller DP, Poms AD, et al. Five-year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148(4):1043–54. https://doi.org/10.1378/chest.15-0300.
McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012;21(123):8–18. https://doi.org/10.1183/09059180.00008211.
Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11(1):2045894020977300. https://doi.org/10.1177/2045894020977300.
Gu S, Hu H, Dong H. Systematic review of the economic burden of pulmonary arterial hypertension. Pharmacoeconomics. 2016;34(6):533–50. https://doi.org/10.1007/s40273-015-0361-0.
Maron BA, Galiè N. Diagnosis, treatment, and clinical management of pulmonary arterial hypertension in the contemporary era: a review. JAMA Cardiol. 2016;1(9):1056–65. https://doi.org/10.1001/jamacardio.2016.4471.
Ghofrani HA, Humbert M. The role of combination therapy in managing pulmonary arterial hypertension. Eur Respir Rev. 2014;23(134):469–75. https://doi.org/10.1183/09059180.00007314 (Epub 2014 Dec 1 PMID: 25445945).
Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–44. https://doi.org/10.1056/NEJMoa1413687.
Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565–86. https://doi.org/10.1016/j.chest.2018.11.030 (Epub 2019 Jan 17. Erratum in: Chest. 2021 Jan;159(1):457. PMID: 30660783).
Kanwar M, Raina A, Lohmueller L, Kraisangka J, Benza R. The use of risk assessment tools and prognostic scores in managing patients with pulmonary arterial hypertension. Curr Hypertens Rep. 2019;21(6):45. https://doi.org/10.1007/s11906-019-0950-y.
McLaughlin VV, Hoeper MM, Channick RN, et al. Pulmonary arterial hypertension-related morbidity is prognostic for mortality. J Am Coll Cardiol. 2018;71(7):752–63. https://doi.org/10.1016/j.jacc.2017.12.010.
McLaughlin VV, Channick R, De Marco T, et al. Results of an expert consensus survey on the treatment of pulmonary arterial hypertension with oral prostacyclin pathway agents. Chest. 2020;157(4):955–65. https://doi.org/10.1016/j.chest.2019.10.043.
Burger CD, Long PK, Shah MR, et al. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest. 2014;146(5):1263–73. https://doi.org/10.1378/chest.14-0193.
Frantz RP, Schilz RJ, Chakinala MM, et al. Hospitalization and survival in patients using epoprostenol for injection in the PROSPECT observational study. Chest. 2015;147(2):484–94. https://doi.org/10.1378/chest.14-1004.
Burke JP, Hunsche E, Regulier E, Nagao M, Buzinec P, Drake IW. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study. Am J Manag Care. 2015;21(3 Suppl):s47–58.
Kim N, Farber HW, Highland K, et al. PCV3 hospitalization rates and association with survival risk at baseline in patients with pulmonary artery hypertension (PAH) receiving selexipag in real-world (RW) clinical practice. Value Health. 2020;23:S486. https://doi.org/10.1016/j.jval.2020.08.494.
Haddad F, Peterson T, Fuh E, et al. Characteristics and outcome after hospitalization for acute right heart failure in patients with pulmonary arterial hypertension. Circ Heart Fail. 2011;4(6):692–9. https://doi.org/10.1161/CIRCHEARTFAILURE.110.949933 (Epub 2011 Sep 9 PMID: 21908586).
Burger CD, Ghandour M, Padmanabhan Menon D, Helmi H, Benza RL. Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes. Clinicoecon Outcomes Res. 2017;24(9):731–9. https://doi.org/10.2147/CEOR.S119117.PMID:29200882;PMCID:PMC5703162.
White RJ, Vonk-Noordegraaf A, Rosenkranz S, et al. Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. Resp Res. 2019;20(1):208. https://doi.org/10.1186/s12931-019-1180-1.
Sikirica M, Iorga SR, Bancroft T, Potash J. The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients. BMC Health Serv Res. 2014;14(1):676. https://doi.org/10.1186/s12913-014-0676-0.
Burger CD, Ozbay AB, Lazarus HM, et al. Treatment patterns and associated health care costs before and after treatment initiation among pulmonary arterial hypertension patients in the United States. J Manag Care Spec Pharm. 2018;24(8):834–42. https://doi.org/10.18553/jmcp.2018.17391.
Sahay S, Tsang Y, Flynn M, Agron P, Dufour R. Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study. Pulm Circ. 2020;10(4):2045894020962917. https://doi.org/10.1177/2045894020962917.
Berger A, Edelsberg J, Teal S, et al. Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study. BMC Pulm Med. 2012;12:75. https://doi.org/10.1186/1471-2466-12-75.
Mathai SC, Hemnes AR, Manaker S, et al. Identifying patients with pulmonary arterial hypertension using administrative claims algorithms. Ann Am Thorac Soc. 2019;16(7):797–806. https://doi.org/10.1513/AnnalsATS.201810-672CME.
Frenkel WJ, Jongerius EJ, Mandjes-van Uitert MJ, van Munster BC, de Rooij SE. Validation of the Charlson Comorbidity Index in acutely hospitalized elderly adults: a prospective cohort study. J Am Geriatr Soc. 2014;62(2):342–6. https://doi.org/10.1111/jgs.12635.
Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164–72. https://doi.org/10.1161/CIRCULATIONAHA.109.898122.
Studer S, Hull M, Pruett J, Elliott C, Tsang Y, Drake W. Retrospective database analysis of treatment patterns among patients with pulmonary arterial hypertension. Pulm Ther. 2020;6(1):79–92. https://doi.org/10.1007/s41030-019-00106-4.
Hoeper MM, Kramer T, Pan Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J. 2017;50(2):1700740. https://doi.org/10.1183/13993003.00740-2017.
Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18. https://doi.org/10.1056/NEJMoa1213917.
Sitbon O, Janis X, Savale L, et al. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J. 2014;43:1691–7. https://doi.org/10.1183/09031936.00116313.
Lajoie AC, Lauziere G, Leg JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4:291–305. https://doi.org/10.1016/S2213-2600(16)00027-8.
Lajoie AC, Lauzière G, Lega JC, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4(4):291–305. https://doi.org/10.1016/S2213-2600(16)00027-8 (Epub 2016 Feb 27. Erratum in: Lancet Respir Med. 2016 Jun;4(6):e34. PMID: 26935844).
Dufour R, Pruett J, Hu N, et al. Healthcare resource utilization and costs for patients with pulmonary arterial hypertension: Real-world documentation of functional class. J Med Econ. 2017;20(11):1178–86. https://doi.org/10.1080/13696998.2017.1363049.
Lang IM, Palazzini M. The burden of comorbidities in pulmonary arterial hypertension. Eur Heart J Suppl. 2019;21(Suppl K):K21–8. https://doi.org/10.1093/eurheartj/suz205.
Xanthouli P, Koegler M, Marra AM, et al. Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up. Respir Res. 2020;21(1):127. https://doi.org/10.1186/s12931-020-01393-1.
U.S. Food & Drug Administration label: sildenafil. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/20895s039s042lbl.pdf. Accessed 28 Apr 2021.
U.S. Food & Drug Administration label: tadalafil. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf. Accessed 28 Apr 2021.
U.S. Food & Drug Administration label: macitentan. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204410s017lbl.pdf. Accessed 28 Apr 2021.
U.S. Food & Drug Administration label: ambrisentan. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022081s033lbl.pdf. Accessed 28 Apr 2021.
U.S. Food & Drug Administration label: bosentan. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021290s012lbl.pdf. Accessed 28 Apr 2021.
U.S. Food & Drug Administration label: iloprost. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021779s009lbl.pdf. Accessed 28 Apr 2021.
U.S. Food & Drug Administration label: selexipag. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207947s000lbl.pdf. Accessed 28 Apr 2021.
U.S. Food & Drug Administration label: treprostinil. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021272s020lbledt.pdf. Accessed 28 Apr 2021.